1,018
Views
30
CrossRef citations to date
0
Altmetric
Research Article

Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis

, , &
Pages 269-278 | Received 02 Aug 2016, Accepted 31 Oct 2016, Published online: 06 Feb 2017

References

  • Mitsumoto H, Chad DA, Pioro EP, Amyotrophic lateral sclerosis. USA: Oxford University Press. 1998.
  • Cozzolino M, Ferri A, Valle C, Carri MT. Mitochondria and ALS: implications from novel genes and pathways. Mol Cell Neurosci. 2013;55:44–9.
  • McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11:246–54.
  • Papadimitriou D, Le Verche V, Jacquier A, Ikiz B, Przedborski S, Re DB. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis. 2010;37:493–502.
  • Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48:629–41.
  • Wallis N, Zagami CJ, Beart PM, O'Shea RD. Combined excitotoxic-oxidative stress and the concept of non-cell autonomous pathology of ALS: insights into motoneuron axonopathy and astrogliosis. Neurochem Int. 2012;61:523–30.
  • DeLoach A, Cozart M, Kiaei A, Kiaei M. A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. Expert Opin Drug Discov. 2015;10:1099–118.
  • Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;3:CD001447.
  • Thomsen G, Gowing G, Sevensen S, Sevenden C. The past, present and future of stem cell clinical trials for ALS. Exp Neurol. 2014;262:127–37.
  • Funakoshi H, Nakamura T. Hepatocyte growth factor (HGF): neurotrophic functions and therapeutic implications or neuronal injury/diseases. Curr Signal Transduct Ther. 2011;6:156–67.
  • Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci. 2002;22:6537–48.
  • Ishigaki A, Aoki M, Nagai M, Warita H, Kato S, Kato M, et al. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J Neuropathol Exp Neurol. 2007;66:1037–44.
  • Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol. 2011;Suppl 1:188–202.
  • Akita H, Takagi N, Ishihara N, Takagi K, Murotomi K, Funakoshi H, et al. Hepatocyte growth factor improves synaptic localization of the NMDA receptor and intracellular signaling after excitotoxic injury in cultured hippocampal neurons. Exp Neurol. 2008;210:83–94.
  • Ishihara N, Takagi N, Niimura M, Takagi K, Nakano M, Tanonaka k, et al. Inhibition of apoptosis-inducing factor translocation is involved in protective effects of hepatocyte growth factor against excitotoxic cell death in cultured hippocampal neurons. J Neurochem. 2005;95:1277–86.
  • Pasinelli P, Houseweart MK, Brown RH, Jr, Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2000;97:13901–6.
  • Kadoyama K, Funakoshi H, Ohya W, Nakamura T. Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci Res. 2007;59:446–56.
  • Tyndall SJ, Walikonis RS. Signaling by hepatocyte growth factor in neurons is induced by pharmacological stimulation of synaptic activity. Synapse. 2007;61:199–204.
  • Shang J, Deguchi K, Ohta Y, Liu N, Zhang X, Tian F, et al. Strong neurogenesis, angiogenesis, synaptogenesis, and antifibrosis of hepatocyte growth factor in rats brain after transient middle cerebral artery occlusion. J Neurosci Res. 2011;89:86–95.
  • Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407:802–9.
  • Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol. 1999;58:459–71.
  • Kadoyama K, Funakoshi H, Ohya-Shimada W, Nakamura T, Matsumoto K, Matsuyama S, et al. Disease-dependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenic mouse model of ALS. Neurosci Res. 2009;65:194–200.
  • Pyun WB, Hahn W, Kim DS, Yoo WS, Lee SD, Won JH, et al. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010;17:1442–52.
  • Hahn W, Pyun WB, Kim DS, Yoo WS, Lee SD, Won JH, et al. Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model. J Gene Med. 2011;13:549–55.
  • Ajroud-Driss S, Christiansen M, Allen JA, Kessler JA. Phase 1/2 open-label dose–escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol Ther. 2013;21:1279–86.
  • Henry TD, Hirsch AT, Goldman J, Wang YL, Lips DL, McMillan WD, et al. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Ther. 2011;18:788–94.
  • Kessler JA, Smith AG, Cha BS, Choi SH, Wymer H, Shaibani A, et al. Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy. Ann Clin Transl Neurol. 2015;2:465–78.
  • Kim JS, Hwang HY, Cho KR, Park EA, Lee W, Paeng JC, et al. Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Ther. 2013;20:717–22.
  • Kibbe MR, Hirsch AT, Medelsohn FO, Daies MG, Pham H, Saucedo J, et al. Safety and efficacy of Plasmid DNA expressing two isoform of hepatocyte growth factor in patients with critical limb ischemia. Gene Ther. 2016;23:306–12.
  • Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045–53.
  • Brinkmann JR, Andres P, Mendoza M, Sanjak M. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci. 1997;147:97–111.
  • Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014; 83:1719–25.
  • Körner S, Kollewe K, Abdulla S, Zapf A, Dengler R, Petri S. Interaction of physical function, quality of life and depression in Amyotrophic lateral sclerosis: characterization of a large patient cohort. BMC Neurol. 2015;15:84.
  • Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.